1-4 of 4
Gyorgy Paragh
Close
Sort by
Journal Articles

Mitochondrial Reprogramming By Bcl-2 Inhibitor Venetoclax Enhances αCD19 CAR-T Cell Fitness and Anti-Tumor Efficacy

Taylor K Mandeville, Cory Mavis, Juan Gu, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Matthew J Cortese, Francisco J. Hernandez-Ilizaliturri
Journal: Blood
Blood (2023) 142 (Supplement 1): 6845.
https://doi.org/10.1182/blood-2023-191051
Published: 2023
Journal Articles

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Taylor Mandeville, Cory Mavis, Juan Gu, Noah Lemoine, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Francisco Hernandez-Ilizaliturri
Journal: Blood
Blood (2022) 140 (Supplement 1): 7398–7399.
https://doi.org/10.1182/blood-2022-170436
Published: 2022
Journal Articles

Contribution of Bcl-2 Inhibitor Venetoclax Toward Anti-CD19 CAR T Cell Efficacy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Taylor K Mandeville, Cory Mavis, Juan Gu, Scott Olejniczak, Gyorgy Paragh, Prasenjit Dey, Francisco J. Hernandez-Ilizaliturri
Journal: Blood
Blood (2021) 138 (Supplement 1): 1719.
https://doi.org/10.1182/blood-2021-154128
Published: 2021
Journal Articles

Evaluation of the Role of Radiological Imaging and Bone Marrow Biopsy in Staging of Cutaneous B-Cell Lymphoma

Pankit Vachhani, MD, Christopher J. Cancino, MD, Paul Bogner, MD, Charles L. Roche, MD, Gyorgy Paragh, MD PhD, Marcelle A. Grassi, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2016) 128 (22): 5326.
https://doi.org/10.1182/blood.V128.22.5326.5326
Published: 2016